Bridging The Gap
Research and Real-World Impact
Neurometry was born from personal experience with delayed diagnosis, driving our Founder to focus on research and collaborate with forward thinking experts in cognitive science. Traditional methods often miss the mark, leading to errors and delays in treatment. Our mission is to replace these outdated practices with precise and remote solutions.
Leveraging business acumen and a deep understanding of biomedical engineering and neuroscience, we bridge the gap between cutting-edge research and practical applications. Our Co-Founder, originally a software engineer, transitioned into biomedical science to explore how technology can improve quality of life. Together, we harness the power of software and neuroscience to build patient-generated evidence for clinicians.
Our dedicated team, including passionate students, works tirelessly to innovate and push the boundaries of cognitive health. Neurometry is dedicated to transforming cognitive health, ensuring every patient gets the accurate, timely care they deserve.
is a biotech and finance entrepreneur with a robust background in statistics. His personal experiences inspired his journey into the biotech sector, leading to significant contributions in MedTech and Biotech. In 2017, he helped facilitate the growth of a MedTech company specializing in cardiology. He then spearheaded the turnaround at AbCelex Technology, focusing on bispecific antibodies for immunization against animal-based diseases, and continued with the spinoff of Orpheus Medica, a small molecule platform targeting pain indications with synthetic cannabinoids.
He played a crucial role as a consultant for Kondor Pharma, aiding in the expansion of its anti-inflammatory platform for neural applications. His work was recognized at the World Economic Forum COVID-19 Response Challenge in 2020, highlighting his prior research in the Economics of Pandemics.
Previously, Omair had a 12-year career in derivatives trading and portfolio management at RBC Royal Bank and BMO Capital Markets. In 2014, he launched a systematic trading fund, Taunton Capital LLP, focused on chaos theory and information signals. He has been a member of the Milken Institute since 2017 and FasterCures since 2020. He holds an MSc in Quantitative Finance from London Business School and an Hon. BA in Econometrics and Theology from the University of Toronto.
Omair’s interdisciplinary expertise and passion for improving quality of life through innovative and economic solutions drive his leadership at Neurometry.
is a distinguished clinical researcher with a diverse 13-year background in software engineering within the Tech and Media sectors. Her journey began with a PhD focused on the fabrication, characterization, and application of disposable microcantilevers for biomedical purposes. She continued her postdoctoral research at the Biomaterials Science Centre, University of Basel,followed by the University Hospital of Psychiatry in Bern.
She served as a researcher and deputy group head at the Gerontechnology and Rehabilitation Group, ARTORG Center at the University of Bern, and as a scientific officer and program manager at Innosuisse, the Swiss Innovation Agency. Her extensive research career spans nanotechnology, biosensors, biomaterials, implant surface characterization, micro/nanofabrication, neuroscience, psychiatry, neurodegenerative diseases, gerontechnology, ambient assisted living, telehealth, and rehabilitation.
She holds a Bachelor of Technology in Computer Science & Engineering from Mangalore University, an MSc in Biomedical Engineering from the University of Bern, a PhD in Biomedical Engineering from the University of Basel and the Paul Scherrer Institute, and a Venia Docendi (PD) from the University of Bern.
Dr. Urwyler’s interdisciplinary expertise and passion for improving quality of life through innovative biomedical solutions make her an invaluable leader at Neurometry.
© 2023 Neurometry Ltd. All rights reserved.
